IGSF11

Summary

IGSF11 (immunoglobulin superfamily member 11, HGNC:16669) is a protein-coding gene on chromosome 3q13.32, encoding Immunoglobulin superfamily member 11 (Q5DX21). Functions as a cell adhesion molecule through homophilic interaction.

IGSF11 is an immunoglobulin (Ig) superfamily member that is preferentially expressed in brain and testis. It shares significant homology with coxsackievirus and adenovirus receptor (CXADR; MIM 602621) and endothelial cell-selective adhesion molecule (ESAM).

Source: NCBI Gene 152404 — RefSeq curated summary.

At a glance

• GWAS associations: 24
• Clinical variants (ClinVar): 68 total
• Druggable target: yes
• MANE Select transcript: NM_001015887

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16669
Approved symbol	IGSF11
Name	immunoglobulin superfamily member 11
Location	3q13.32
Locus type	gene with protein product
Status	Approved
Aliases	BT-IgSF, MGC35227, Igsf13, VSIG3, CT119
Ensembl gene	ENSG00000144847
Ensembl biotype	protein_coding
OMIM	608351
Entrez	152404

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000354673, ENST00000393775, ENST00000425327, ENST00000441144, ENST00000459718, ENST00000480431, ENST00000483401, ENST00000489689, ENST00000491903, ENST00000494802, ENST00000874675, ENST00000874676, ENST00000874677, ENST00000947895

RefSeq mRNA: 11 — MANE Select: NM_001015887 NM_001015887, NM_001353318, NM_001353319, NM_001353320, NM_001353321, NM_001353322, NM_001353323, NM_001353324, NM_001353325, NM_001353326, NM_152538

CCDS: CCDS2983, CCDS46891, CCDS87123, CCDS87124, CCDS87125

Canonical transcript exons

ENST00000393775 — 7 exons

Exon	Start	End
ENSE00000967477	118926101	118926256
ENSE00001241518	118904648	118904798
ENSE00001241526	118905596	118905718
ENSE00001851354	118900557	118902961
ENSE00001953097	119034531	119034846
ENSE00003497813	118928509	118928716
ENSE00003623791	118930112	118930275

Expression profiles

Bgee: expression breadth ubiquitous, 186 present calls, max score 97.36.

FANTOM5 (CAGE): breadth broad, TPM avg 3.2818 / max 192.4690, expressed in 295 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43964	1.2343	195
43963	1.1153	180
43962	0.2324	103
43966	0.2145	87
43960	0.1602	83
43965	0.1395	89
43961	0.1077	67
43967	0.0343	18
43970	0.0288	3
43969	0.0106	6

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.36	gold quality
oocyte	CL:0000023	97.27	gold quality
corpus callosum	UBERON:0002336	92.11	gold quality
left testis	UBERON:0004533	91.47	gold quality
right testis	UBERON:0004534	90.85	gold quality
spinal cord	UBERON:0002240	90.00	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	89.99	gold quality
testis	UBERON:0000473	89.92	gold quality
medial globus pallidus	UBERON:0002477	89.52	gold quality
inferior vagus X ganglion	UBERON:0005363	89.27	gold quality
globus pallidus	UBERON:0001875	88.81	gold quality
caudate nucleus	UBERON:0001873	86.60	gold quality
ventricular zone	UBERON:0003053	86.40	gold quality
subthalamic nucleus	UBERON:0001906	86.18	gold quality
Brodmann (1909) area 46	UBERON:0006483	86.10	gold quality
putamen	UBERON:0001874	85.83	gold quality
medulla oblongata	UBERON:0001896	85.10	gold quality
substantia nigra	UBERON:0002038	85.07	gold quality
midbrain	UBERON:0001891	84.66	gold quality
nucleus accumbens	UBERON:0001882	84.56	gold quality
prefrontal cortex	UBERON:0000451	84.40	gold quality
amygdala	UBERON:0001876	84.16	gold quality
Ammon’s horn	UBERON:0001954	84.00	gold quality
pons	UBERON:0000988	83.84	gold quality
temporal lobe	UBERON:0001871	83.79	gold quality
postcentral gyrus	UBERON:0002581	83.78	gold quality
middle temporal gyrus	UBERON:0002771	83.56	gold quality
Brodmann (1909) area 9	UBERON:0013540	83.33	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.24	gold quality
entorhinal cortex	UBERON:0002728	83.16	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.70
E-CURD-10	no	8.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

156 targeting IGSF11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AN	99.97	70.91	2817

Literature-anchored findings (GeneRIF, showing 7)

• Molecular cloning of BT-IgSF which is preferentially expressed by brain and testis (PMID:12207903)
• cell adhesion-inducing function of BT-IgSF suggests a role of the cell surface molecule in the development/function of the central nervous system and spermatogenesis (PMID:15795899)
• IGSF11 is a good candidate of cancer-testis antigen. Furthermore, suppression of IGSF11 by siRNA retarded the growth of gastric cancer cells. (PMID:16108831)
• Concerted role for IgSF11 and PSD-95 in the regulation of AMPAR-mediated synaptic transmission and plasticity. (PMID:26595655)
• this study shows that VSIG-3 as a ligand of VISTA inhibits human T-cell function (PMID:30220083)
• Structural Basis of VSIG3: The Ligand for VISTA. (PMID:33841409)
• IGSF11 is required for pericentric heterochromatin dissociation during meiotic diplotene. (PMID:34491997)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	igsf11	ENSDARG00000109783
mus_musculus	Igsf11	ENSMUSG00000022790
rattus_norvegicus	Igsf11	ENSRNOG00000001525

Paralogs (14): VSIG2 (ENSG00000019102), VSIG1 (ENSG00000101842), VSIR (ENSG00000107738), GPA33 (ENSG00000143167), ESAM (ENSG00000149564), CXADR (ENSG00000154639), JAM2 (ENSG00000154721), F11R (ENSG00000158769), MXRA8 (ENSG00000162576), JAM3 (ENSG00000166086), CLMP (ENSG00000166250), MUC15 (ENSG00000169550), VSTM2B (ENSG00000187135), VSIG8 (ENSG00000243284)

Protein

Protein identifiers

Immunoglobulin superfamily member 11 — Q5DX21 (reviewed: Q5DX21)

Alternative names: Brain and testis-specific immunoglobulin superfamily protein, V-set and immunoglobulin domain-containing protein 3

All UniProt accessions (5): Q5DX21, C9IZX3, C9JAD3, C9JBA5, C9JMW0

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a cell adhesion molecule through homophilic interaction. Stimulates cell growth.

Subcellular location. Cell membrane.

Tissue specificity. Abundantly expressed in testis and ovary and to a lower extent in brain, kidney and skeletal muscle.

Post-translational modifications. N-glycosylated.

Miscellaneous. The last 20 cytoplasmic amino acids are not required for the cell adhesion function.

Isoforms (3)

UniProt ID	Names	Canonical?
Q5DX21-1	1	yes
Q5DX21-2	2
Q5DX21-3	3

RefSeq proteins (11): NP_001015887, NP_001340247, NP_001340248, NP_001340249, NP_001340250, NP_001340251, NP_001340252, NP_001340253, NP_001340254, NP_001340255, NP_689751 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR042758	IGSF11	Family

Pfam: PF07686, PF13927

UniProt features (21 total): sequence variant 3, sequence conflict 3, disulfide bond 2, splice variant 2, topological domain 2, domain 2, signal peptide 1, chain 1, glycosylation site 1, transmembrane region 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5DX21-F1	73.38	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 378

Disulfide bonds (2): 44–120, 165–215

Glycosylation sites (1): 102

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 104 (showing top): GOBP_SYNAPSE_ASSEMBLY, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_CELL_CELL_SIGNALING, GOBP_CELL_CELL_ADHESION, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_REGULATION_OF_SYNAPTIC_PLASTICITY, GOBP_REGULATION_OF_SYNAPSE_ASSEMBLY, ATTCTTT_MIR186, GOBP_SYNAPTIC_SIGNALING, GOBP_POSITIVE_REGULATION_OF_LONG_TERM_SYNAPTIC_POTENTIATION, GOBP_REGULATION_OF_SYNAPSE_STRUCTURE_OR_ACTIVITY, GOBP_LONG_TERM_SYNAPTIC_POTENTIATION, GOBP_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_LONG_TERM_SYNAPTIC_POTENTIATION

GO Biological Process (7): homophilic cell-cell adhesion (GO:0007156), obsolete cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742), trans-synaptic signaling (GO:0099537), positive regulation of long-term synaptic potentiation (GO:1900273), regulation of presynapse assembly (GO:1905606), cell adhesion (GO:0007155), regulation of synaptic plasticity (GO:0048167)

GO Molecular Function (2): ionotropic glutamate receptor binding (GO:0035255), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), cell-cell junction (GO:0005911), synapse (GO:0045202), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	1
synaptic signaling	1
positive regulation of synaptic transmission	1
long-term synaptic potentiation	1
regulation of long-term synaptic potentiation	1
regulation of synapse assembly	1
presynapse assembly	1
regulation of presynapse organization	1
cellular process	1
modulation of chemical synaptic transmission	1
regulation of biological quality	1
glutamate receptor binding	1
binding	1
membrane	1
cell periphery	1
anchoring junction	1
cell junction	1
cellular anatomical structure	1

Protein interactions and networks

STRING

850 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IGSF11	VSIR	Q9H7M9	740
IGSF11	CSF1R	P07333	573
IGSF11	HAVCR2	Q8TDQ0	571
IGSF11	LAG3	P18627	561
IGSF11	CTLA4	P16410	551
IGSF11	TIGIT	Q495A1	541
IGSF11	BTLA	Q7Z6A9	484
IGSF11	KCNJ13	O60928	479
IGSF11	VSIG1	Q86XK7	454
IGSF11	TNFRSF18	Q9Y5U5	433
IGSF11	PPP1R36	Q96LQ0	420
IGSF11	LRFN2	Q9ULH4	406
IGSF11	DNAJC24	Q6P3W2	406
IGSF11	MAU2	Q9Y6X3	400
IGSF11	MCHR1	Q99705	399

IntAct

3 interactions, top by confidence:

A	B	Type	Score
IGSF11	IGSF11	psi-mi:“MI:0915”(physical association)	0.400
IGSF10	IGSF11	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (2): IGSF11 (Two-hybrid), IGSF11 (Reconstituted Complex)

ESM2 similar proteins: A0A0R4IGV4, A0A8M2B818, A0JM41, A2VD98, B0CLX4, B6ZK77, D3YX43, F1LW30, O00241, O18906, O54901, O88775, O95256, P00545, P04218, P0C673, P10522, P13369, P17948, P21995, P27931, P35916, P35917, P35969, P37301, P42071, P42703, P53767, Q08DK1, Q15762, Q58EG3, Q5DX21, Q5FWR8, Q5R412, Q5U2P2, Q5VJ70, Q6GMZ9, Q6PCB8, Q6X936, Q7TSN7

Diamond homologs: P01635, P01636, P01670, P01671, P01674, P01685, P01696, P04945, P09564, P0C673, P50283, Q08DK1, Q5DX21, Q5U2P2, A2AJ76, D3YXG0, P78310, Q08E08, Q29RR6, Q4KLY3, Q5R764, Q6AYD4, Q6WRH9, Q6WRI0, Q86XK7, Q8K1G0, Q8NDA2, Q8R373, Q90W79, Q90Y50, Q91664, Q925F2, Q92626, Q96IQ7, Q96JA1, Q96RW7, Q99795, Q9D2J4, Q9H6B4, Q9JMB8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3146 predictions. Top by Δscore:

Variant	Effect	Δscore
3:118902958:CTCT:C	acceptor_gain	1.0000
3:118902960:CT:C	acceptor_gain	1.0000
3:118902962:C:CC	acceptor_gain	1.0000
3:118904643:CAAA:C	donor_gain	1.0000
3:118904644:AAACC:A	donor_loss	1.0000
3:118904645:AACCT:A	donor_loss	1.0000
3:118904646:A:C	donor_loss	1.0000
3:118905594:A:AC	donor_gain	1.0000
3:118905595:C:CC	donor_gain	1.0000
3:118905719:C:CC	acceptor_gain	1.0000
3:118926099:AC:A	donor_gain	1.0000
3:118926100:CC:C	donor_gain	1.0000
3:118926257:C:CC	acceptor_gain	1.0000
3:118930108:ATACC:A	donor_loss	1.0000
3:118930110:A:AT	donor_loss	1.0000
3:118930273:CAC:C	acceptor_gain	1.0000
3:118930276:C:CA	acceptor_loss	1.0000
3:118930276:C:CC	acceptor_gain	1.0000
3:118931311:A:AC	donor_gain	1.0000
3:118931312:A:C	donor_gain	1.0000
3:118932408:C:A	donor_gain	1.0000
3:118958427:T:A	donor_gain	1.0000
3:118902957:CCTCT:C	acceptor_gain	0.9900
3:118902958:CTCTC:C	acceptor_gain	0.9900
3:118902959:TCT:T	acceptor_gain	0.9900
3:118902959:TCTCT:T	acceptor_gain	0.9900
3:118902960:CTC:C	acceptor_gain	0.9900
3:118902961:TC:T	acceptor_loss	0.9900
3:118902961:TCT:T	acceptor_gain	0.9900
3:118902962:C:G	acceptor_gain	0.9900

AlphaMissense

2791 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:118905655:C:G	C215S	1.000
3:118905656:A:T	C215S	1.000
3:118926147:C:A	W178C	1.000
3:118926147:C:G	W178C	1.000
3:118926149:A:G	W178R	1.000
3:118926149:A:T	W178R	1.000
3:118928581:A:C	Y118D	1.000
3:118905642:A:C	N219K	0.999
3:118905642:A:T	N219K	0.999
3:118905654:G:C	C215W	0.999
3:118905655:C:T	C215Y	0.999
3:118905656:A:G	C215R	0.999
3:118905662:A:C	Y213D	0.999
3:118926148:C:G	W178S	0.999
3:118926186:A:C	C165W	0.999
3:118926187:C:G	C165S	0.999
3:118926187:C:T	C165Y	0.999
3:118926188:A:G	C165R	0.999
3:118926188:A:T	C165S	0.999
3:118926236:A:G	C149R	0.999
3:118928520:A:G	L138P	0.999
3:118928574:C:G	C120S	0.999
3:118928575:A:G	C120R	0.999
3:118928575:A:T	C120S	0.999
3:118905621:A:C	C226W	0.998
3:118905655:C:A	C215F	0.998
3:118926160:G:C	P174R	0.998
3:118926166:G:T	P172H	0.998
3:118926193:A:G	L163P	0.998
3:118926234:G:C	C149W	0.998

dbSNP variants (sampled 300 via entrez): RS1000031433 (3:118946585 G>A), RS1000032365 (3:119074138 A>C), RS1000034318 (3:119086273 T>C), RS1000034569 (3:119022563 G>A), RS1000039251 (3:118928814 C>T), RS1000040493 (3:119019729 T>C), RS1000067000 (3:119107052 G>C), RS1000082237 (3:119129092 T>A), RS1000083079 (3:118948933 C>A,T), RS1000083181 (3:119143559 C>A,T), RS1000092295 (3:118929217 T>A,C), RS1000107436 (3:119015947 A>G), RS1000121460 (3:118974785 T>C), RS1000130003 (3:118952952 T>C), RS1000139335 (3:118915520 A>G)

Disease associations

OMIM: gene MIM:608351 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

24 associations (top):

Study	Trait	p-value
GCST001651_37	Response to amphetamines	9.000000e-06
GCST001762_178	Obesity-related traits	1.000000e-06
GCST002541_1	Menarche (age at onset)	2.000000e-27
GCST003059_8	Parkinson’s disease	1.000000e-06
GCST003123_11	Severe influenza A (H1N1) infection	2.000000e-10
GCST003559_2	Bone mineral density (hip)	1.000000e-09
GCST003559_4	Bone mineral density (hip)	4.000000e-10
GCST004904_138	Body mass index	3.000000e-09
GCST005987_30	Albumin-globulin ratio	2.000000e-08
GCST007323_18	Risk-taking tendency (4-domain principal component model)	9.000000e-09
GCST007323_79	Risk-taking tendency (4-domain principal component model)	2.000000e-10
GCST007326_67	Number of sexual partners	8.000000e-09
GCST007327_19	Smoking status (ever vs never smokers)	2.000000e-08
GCST007327_212	Smoking status (ever vs never smokers)	4.000000e-16
GCST007327_90	Smoking status (ever vs never smokers)	7.000000e-10
GCST007327_96	Smoking status (ever vs never smokers)	1.000000e-09
GCST008358_3	Response to cognitive-behavioural therapy in anxiety and major depressive disorders	5.000000e-06
GCST008360_5	Response to cognitive-behavioural therapy in anxiety disorder	6.000000e-06
GCST008595_38	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	4.000000e-08
GCST008810_25	Smoking initiation (ever regular vs never regular)	8.000000e-09
GCST008810_53	Smoking initiation (ever regular vs never regular)	9.000000e-10
GCST008839_418	Height	4.000000e-10
GCST010002_436	Refractive error	6.000000e-16
GCST011703_63	Smoking initiation	1.000000e-09

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0005118	IGFBP-1 measurement
EFO:0004703	age at menarche
EFO:1001488	influenza A (H1N1)
EFO:0007702	hip bone mineral density
EFO:0004340	body mass index
EFO:0005128	albumin:globulin ratio measurement
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:0007820	cognitive behavioural therapy
EFO:0004337	intelligence
EFO:0004784	self reported educational attainment
EFO:0005670	smoking initiation

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5291534 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	6
entinostat	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	increases expression	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
licochalcone B	increases expression	1
Decitabine	affects expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Cisplatin	affects expression	1
Estradiol	affects binding, increases expression	1
Lead	affects expression	1
Lipopolysaccharides	increases expression, affects response to substance	1
Methapyrilene	increases methylation	1
Nickel	decreases expression	1
Silicon Dioxide	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5233350	Binding	Binding affinity to recombinant human VSIG3 (23 to 241 residues extracellular binding domain expressed in Escherichia coli BL21 (DE3) incubated for 30 mins by microscale thermophoresis analysis	VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses. — RSC Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.